Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.41 |
| ▸ | SMPD3 | Q9NY59 | 8/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20359569 | 1.00 | CNR2 (0.41) | CNR2SMPD3CNR1FAAHABHD6 | |
| SCHEMBL20365220 | 0.91 | CNR2 (0.41) | CNR2SMPD3BTK | |
| SCHEMBL20358723 | 0.82 | BTK (0.40) | CNR2BTK | |
| SCHEMBL20358713 | 0.82 | BTK (0.40) | CNR2BTK | |
| SCHEMBL20365226 | 0.82 | TRPV1 (0.40) | CNR2BTK | |
| SCHEMBL20360088 | 0.82 | MC4R (0.38) | BTKAOC3 | |
| SCHEMBL20360092 | 0.82 | MC4R (0.38) | BTKAOC3 | |
| SCHEMBL20360087 | 0.82 | CCR8 (0.34) | FFAR4BTKMCHR1 | |
| SCHEMBL20360086 | 0.82 | CCR8 (0.34) | FFAR4BTKMCHR1 | |
| SCHEMBL20358961 | 0.81 | CNR2 (0.48) | CNR2SMPD3MCHR1HRH3CCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LCK | CNR2 1439/4885SMPD3 2143/4885CNR1 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.